Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Gross Margin: 2010-2025

Historic Gross Margin for Ligand Pharmaceuticals (LGND) over the last 16 years, with Sep 2025 value amounting to 96.71%.

  • Ligand Pharmaceuticals' Gross Margin rose 143.00% to 96.71% in Q3 2025 from the same period last year, while for Sep 2025 it was 94.27%, marking a year-over-year increase of 75.00%. This contributed to the annual value of 93.37% for FY2024, which is 138.00% up from last year.
  • Ligand Pharmaceuticals' Gross Margin amounted to 96.71% in Q3 2025, which was up 2.99% from 93.90% recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Gross Margin ranged from a high of 96.71% in Q3 2025 and a low of 57.10% during Q4 2022.
  • Over the past 3 years, Ligand Pharmaceuticals' median Gross Margin value was 93.37% (recorded in 2024), while the average stood at 92.82%.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Gross Margin plummeted by 2,165bps in 2022, and later spiked by 3,706bps in 2023.
  • Ligand Pharmaceuticals' Gross Margin (Quarterly) stood at 78.75% in 2021, then tumbled by 2,165bps to 57.10% in 2022, then surged by 3,706bps to 94.16% in 2023, then crashed by 79bps to 93.37% in 2024, then skyrocketed by 143bps to 96.71% in 2025.
  • Its Gross Margin stands at 96.71% for Q3 2025, versus 93.90% for Q2 2025 and 89.30% for Q1 2025.